Media Articles Related to Ella (Ulipristal)
Picture of Rubella 1
Source: MedicineNet German Measles Specialty [2014.12.10]
Title: Picture of Rubella 1
Created: 10/20/2009 5:08:00 PM
Last Editorial Review: 12/10/2014 12:00:00 AM
Point of Contention: The Debate Over Morcellation
Source: MedPage Today Endocrinology [2014.12.04]
(MedPage Today) -- After FDA warning, some clinicians still defend the procedure.
Mouse Study Suggests Antibiotics May Aid Salmonella's Spread in Animals
Source: MedicineNet Food Poisoning Specialty [2014.10.21]
Title: Mouse Study Suggests Antibiotics May Aid Salmonella's Spread in Animals
Category: Health News
Created: 10/20/2014 12:00:00 AM
Last Editorial Review: 10/21/2014 12:00:00 AM
EPA Unveils New Bug Repellant Labeling
Source: MedicineNet Lyme Disease Specialty [2014.07.21]
Title: EPA Unveils New Bug Repellant Labeling
Category: Health News
Created: 7/18/2014 12:36:00 PM
Last Editorial Review: 7/21/2014 12:00:00 AM
Source: MedicineNet Bioterrorism Specialty [2014.04.18]
Category: Diseases and Conditions
Created: 1/13/2010 4:06:00 PM
Last Editorial Review: 4/18/2014 12:00:00 AM
Published Studies Related to Ella (Ulipristal)
Ulipristal acetate - safety and pharmacokinetics following multiple doses of
10-50Â mg per day. 
N-mono-demethylated metabolite, PGL4002, were investigated in women... CONCLUSION: Daily administration of UPA at therapeutic and
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. [2010.02.13]
BACKGROUND: Emergency contraception can prevent unintended pregnancies, but current methods are only effective if used as soon as possible after sexual intercourse and before ovulation. We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception... INTERPRETATION: Ulipristal acetate provides women and health-care providers with an effective alternative for emergency contraception that can be used up to 5 days after unprotected sexual intercourse. FUNDING: HRA Pharma. Copyright 2010 Elsevier Ltd. All rights reserved.
Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly
delays follicular rupture. 
mm... CONCLUSIONS: This study demonstrates that UPA can significantly delay follicular
Randomised comparison of the FerX Ella antireflux stent and the ultraflex stent: proton pump inhibitor combination for prevention of post-stent reflux in patients with esophageal carcinoma involving the esophago-gastric junction. [2008.05]
BACKGROUND AND AIM: Metal stents placed across the gastroesophageal junction in patients with malignant dysphagia frequently present with reflux symptoms. We compared an antireflux stent with a standard open stent used in combination with proton pump inhibitor medication... CONCLUSION: The antireflux stent had no demonstrable advantages compared to the combination of standard open stent and proton pump inhibitor medication.
[Selective progesterone receptor modulator (ulipristal acetate--a new option in
the pharmacological treatment of uterine fibroids in women]. [Article in Polish] 
Uterine leiomyomata (fibroids) are very common, mostly benign tumors in women of
reproductive age... The presented results on the application UPA in the medical treatment of
symptomatic uterine fibroids are very promising and gynecologists are given a new
Clinical Trials Related to Ella (Ulipristal)
SX ELLA Esophageal Degradable BD Stent System [Recruiting]
CDB-2914 for Abnormal Uterine Bleeding in Premenopausal Women [Not yet recruiting]
- CDB-2914 is a hormone that blocks progesterone, which is necessary for maintaining
pregnancy. In women with fibroid tumors, CDB-2914 shrank the tumors. In many cases,
menstrual periods stopped during treatment. Because CDB-2914 decreased or stopped menstrual
bleeding in women with fibroids, it may be able to treat abnormal periods in women without
- To see whether CDB-2914 can treat abnormal uterine bleeding in premenopausal women.
- Premenopausal women who have abnormal uterine bleeding that is not caused by fibroids.
- Participants will be screened with a physical exam and medical history. They will also
have blood and urine tests. An ultrasound with fluid of the uterus will test for
fibroids. Uterine cells will be collected for biopsy.
- For the next three menstrual cycles, participants will take either CDB-2914 or a
placebo. Treatment will be studied with blood tests and symptom diaries.
- At the end of the treatment, participants have three options. They can have surgery at
the Clinical Center or have another 3 months of CDB-2914. The third option is to stop
treatment at the Clinical Center.
- Surgery will be either uterine ablation or hysterectomy. Only women older than age 33
may have a hysterectomy. Blood and urine samples will be collected after surgery.
- Both surgery and further treatment participants will have followup exams.
- All participants will have a final followup exam 1 year after stopping treatment.
Study to Evaluate the Safety and Efficacy of Two Contraceptive Vaginal Rings Delivering a Daily Dose of 1500 or 2500 Î¼g of CDB-2914 [Recruiting]
Ulipristal for Endometriosis-related Pelvic Pain [Not yet recruiting]
The aim of this research is to assess the benefit of a medication (ulipristal) for
alleviation of symptoms in women with chronic, endometriosis-related pelvic pain.
Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella [Recruiting]
The study is aimed at assessing the clinical follow-up and the outcomes of pregnancies
exposed to ella, whether due to failure of the emergency contraception or inadvertent
exposure during pregnancy.
Reports of Suspected Ella (Ulipristal) Side Effects
Unintended Pregnancy (4),
Maternal Exposure During Pregnancy (3),
Drug Ineffective (2),
DRY Mouth (2),
Drug Prescribing Error (2),
Drug Interaction (1),
Pregnancy After Post Coital Contraception (1),
Menstrual Disorder (1),
Menstruation Irregular (1), more >>